<DOC>
	<DOCNO>NCT00001567</DOCNO>
	<brief_summary>This study begin efficacy study interferon alpha-2a patient hairy cell leukemia . It observe patient respond interferon , complete response obtain . Studies do elsewhere confirm low complete remission rate . Once interferon stop , nearly uniformly disease progression require reinstitution therapy observe . There appear patient require therapy receive 12 18 month continuous interferon treatment . Because finding , order evaluate safety efficacy long-term recombinant interferon-alpha ( IFN-Alpha ) patient hairy cell leukemia , opt administer interferon continuously patient initially responsive drug . Of 53 evaluable patient ( 56 enter study ) , one complete remission , 41 partial remission , 1 minor response , 9 patient stable disease 1 patient disease progression . Fourteen patient continue receive interferon without interruption median duration continuous interferon treatment 9.2 year . Thirty-four patient discontinue interferon variety reason , common development acquire interferon resistance association interferon antibody . The resistance interferon manifest early , first 18 month treatment , except two case . An important finding study continue slow , significant , hematologic improvement absolute granulocyte platelet count beyond 18 month therapy , thereby indicate prolong treatment result continue benefit rather production antibody subsequent development interferon resistance . Although clear study hairy cell leukemia control long-term interferon , long follow-up necessary determine continuous therapy interferon well intermittent therapy . The optimal therapy hairy cell leukemia remain open discussion . Although early report suggest 2-chlorodeoxyadenosine curative , additional study longer period follow suggest many 30 % patient relapse . This study provide instance continuous long term treatment interferon evaluate . This provide opportunity evaluate long term toxicity chronic interferon therapy , long term efficacy treatment evaluate potential benefit long term interferon prevent second malignancy , complication note 15 % patient treated fashion . After initial clinical evaluation , patient give 3 million unit recombinant IFN-Alpha subcutaneously daily 4 6 month . In respond patient , maintenance therapy give dose three million unit subcutaneously 3 time per week . Responding patient continue therapy indefinitely .</brief_summary>
	<brief_title>A Phase II Efficacy Study Roferon-A Hairy Cell Leukemia</brief_title>
	<detailed_description>This study begin efficacy study interferon alpha-2a patient hairy cell leukemia . It observe patient respond interferon , complete response obtain . Studies do elsewhere confirm low complete remission rate . Once interferon stop , nearly uniform disease progression require reinstitution therapy observe . There appear patient require therapy receive 12 18 month continuous interferon treatment . Because finding , order evaluate safety efficacy long-term recombinant interferon-alpha ( IFN-Alpha ) patient hairy cell leukemia , opt administer interferon continuously patient initially responsive drug . Of 53 evaluable patient ( 56 enter study ) , one complete remission , 41 partial remission , 1 minor response , 9 patient stable disease 1 patient disease progression . Fourteen patient continue receive interferon without interruption median duration continuous interferon treatment 9.2 year . Thirty-four patient discontinue interferon variety reason , common development acquire interferon resistance association interferon antibody . The resistance interferon manifest early , first 18 month treatment , except two case . An important finding study continue slow , significant , hematologic improvement absolute granulocyte platelet count beyond 18 month therapy , thereby indicate prolong treatment result continue benefit rather production antibody subsequent development interferon resistance . Although clear study hairy cell leukemia control long-term interferon , long follow-up necessary determine continuous therapy interferon well intermittent therapy . The optimal therapy hairy cell leukemia remain open discussion . Although early report suggest 2-chlorodeoxyadenosine curative , additional study longer period follow suggest many 30 % patient relapse . This study provide instance continuous long term treatment interferon evaluate . This provide opportunity evaluate long term toxicity chronic interferon therapy , long term efficacy treatment evaluate potential benefit long term interferon prevent second malignancy , complication note 15 % patient treated fashion . After initial clinical evaluation , patient give 3 million unit recombinant IFN-Alpha subcutaneously daily 4 6 month . In respond patient , maintenance therapy give dose 3 million unit subcutaneously 3 time per week . Responding patient continue therapy indefinitely .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Age 1870 . Patients must morphologically identifiable hairy cell peripheral blood bone marrow , tissue biopsy least one following : 1 ) Positive stain tartrateresistant acid phosphatase 2 ) Electron microscopy compatible hairy cell . Patients must ambulatory expect survival great 16 week willing able give write informed consent . Patients must disease assessable , define : 1 ) Pancytopenia 2 ) Bone marrow leukemic infiltrate 3 ) Lymphadenopathy , splenomegaly , hepatomegaly . Patients must require palliative chemotherapy , immunotherapy hormonal therapy treatment prescribe protocol . Patients must test Hepatitis B surface antigen within one week entry study . No pregnant lactate woman . No fertile men woman , unless use effective contraception . No patient unstable angina . Patients Class III IV cardiovascular disease may enter medical clearance cardiology consultant . No patient severe intercurrent infection patient surgery within past four week unless fully recover . No patient impair renal function ( serum creatinine great 1.8 ) . No patient impaired hepatic function ( total bilirubin great 1.4 ) . No patient serum calcium great 12 mg/dl . No patient performance status less equal 60 % Karnofsky scale . No patient prior ( leukocyte fibroblast ) interferon therapy . No patient unable carry treatment program . No patient le 20,000 per cu mm platelet clinical bleed disorder ; must present patient exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>Follow-Up Study</keyword>
	<keyword>Relapse-Free Survival</keyword>
	<keyword>Serum Soluble IL-2 Receptor</keyword>
	<keyword>Hematologic Malignancy</keyword>
	<keyword>Chronic Therapy</keyword>
</DOC>